Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers
- PMID: 20127405
- DOI: 10.1007/s10549-010-0761-y
Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers
Abstract
The purpose of this article is to evaluate the prognostic value of androgen receptor (AR) expression in patients with estrogen receptor (ER)-positive breast cancer, treated with endocrine therapy, with or without the addition of chemotherapy. A consecutive series of 953 patients with ER-positive breast cancer, treated between 1998 and 2003, was selected. Repeated immunohistochemistry confirmed the expression of ER in the tumor of 938 patients. AR expression was measured by immunohistochemistry. The Kaplan-Meier method, logrank test and multivariate Cox models were used to explore the impact of AR expression on time to relapse (TTR) and disease specific survival (DSS) in all patients and in subgroups treated with chemo-endocrine therapy or endocrine therapy alone. AR immunoreactivity was assessable in 859 tumors and positive in 609 (70.9%). AR expression was a significant marker of good prognosis for TTR (P = 0.001) and DSS (P < 0.001). This effect was particularly evident in the group of patients receiving chemo-endocrine therapy (TTR (P = 0.015) and DSS (P < 0.001)). Cox models confirmed AR as an independent variable for both TTR (P = 0.003, HR 0.444, 95%CI 0.258-0.765) and DSS (P < 0.001, HR 0.135, 95%CI 0.054-0.337). Thus, we focused on ER-positive luminal B breast cancer that may be selected for chemotherapy because of their more aggressive immunophenotype. In this subset AR expression identified a group of patients with better prognosis for TTR (P = 0.017, HR 0.521, 95%CI 0.306-0.888) and DSS (P = 0.001, HR 0.276, 95% CI 0.130-0.588). AR expression is an independent prognostic factor of better outcome in patients with ER-positive breast cancers.
Comment in
-
The androgen receptor in breast cancer: learning from the past.Breast Cancer Res Treat. 2010 Dec;124(3):619-21. doi: 10.1007/s10549-010-0864-5. Epub 2010 Mar 31. Breast Cancer Res Treat. 2010. PMID: 20354779 No abstract available.
Similar articles
-
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.J Natl Cancer Inst. 2008 Oct 1;100(19):1380-8. doi: 10.1093/jnci/djn309. Epub 2008 Sep 23. J Natl Cancer Inst. 2008. PMID: 18812550 Free PMC article.
-
Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.J Natl Cancer Inst. 2005 Sep 7;97(17):1254-61. doi: 10.1093/jnci/dji249. J Natl Cancer Inst. 2005. PMID: 16145046
-
Higher expression of androgen receptor is a significant predictor for better endocrine-responsiveness in estrogen receptor-positive breast cancers.Breast Cancer Res Treat. 2012 May;133(1):311-20. doi: 10.1007/s10549-011-1950-z. Epub 2012 Jan 10. Breast Cancer Res Treat. 2012. PMID: 22231421
-
Adjuvant chemotherapy in luminal breast cancers.Breast. 2011 Oct;20 Suppl 3:S128-31. doi: 10.1016/S0960-9776(11)70309-5. Breast. 2011. PMID: 22015279 Review.
-
Disease related indicators for a proper choice of adjuvant treatments.Breast. 2011 Oct;20 Suppl 3:S162-4. doi: 10.1016/S0960-9776(11)70317-4. Breast. 2011. PMID: 22015287 Review.
Cited by
-
Androgen receptor in breast cancer: The "5W" questions.Front Endocrinol (Lausanne). 2022 Aug 30;13:977331. doi: 10.3389/fendo.2022.977331. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36111296 Free PMC article. Review.
-
Androgen receptor protein levels are significantly reduced in serous ovarian carcinomas compared with benign or borderline disease but are not altered by cancer stage or metastatic progression.Horm Cancer. 2013 Jun;4(3):154-64. doi: 10.1007/s12672-013-0135-0. Epub 2013 Feb 27. Horm Cancer. 2013. PMID: 23443946 Free PMC article.
-
Delineating the role of nuclear receptors in colorectal cancer, a focused review.Discov Oncol. 2024 Feb 19;15(1):41. doi: 10.1007/s12672-023-00808-x. Discov Oncol. 2024. PMID: 38372868 Free PMC article. Review.
-
Estrogen Receptor Positive Breast Cancer with High Expression of Androgen Receptor has Less Cytolytic Activity and Worse Response to Neoadjuvant Chemotherapy but Better Survival.Int J Mol Sci. 2019 May 30;20(11):2655. doi: 10.3390/ijms20112655. Int J Mol Sci. 2019. PMID: 31151151 Free PMC article.
-
Clinical verification of sensitivity to preoperative chemotherapy in cases of androgen receptor-expressing positive breast cancer.Br J Cancer. 2016 Jan 12;114(1):14-20. doi: 10.1038/bjc.2015.434. Br J Cancer. 2016. PMID: 26757422 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous